HANGZHOU, China, April 6, 2016 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. has achieved another important milestone with its first implants in Latin America. This is the first time ever for a Chinese medical device company to bring an innovative Transcatheter Pulmonary Valve to Latin America.
On March 28, 2016, three top Latin American doctors Dr. Francisco Garay from Chile, Dr. Carlos Pedra from Brazil and Dr. Alejandro Peirone from Argentina joined together at the Catholic University in Santiago, Chile, to treat patients using the Venus Pulmonary Valve. The LATAM team was assisted by Venus proctors Dr. Ziyad Hijazi, Dr. Qiling Cao from Chicago and Dr. Xin Pan from Shanghai. They successfully implanted the Venus Pulmonary Valves in three young patients via catheter and without the need for invasive surgery. The implanted valves resumed the normal function of the pulmonary arteries of the patients immediately.
These three patients, age 12-14, had to undergo TOF surgical procedures during their first year in order to treat the narrowed pulmonary artery. With a damaged or without the pulmonary valve after the surgery, patients would experience weakness and would not be able to enjoy an active life style. The current available option is to implant a surgical prosthetic valve, however that procedure is very traumatic and requires an open chest surgery.
Venus Medtech (Hangzhou) Inc. has developed an innovative minimally invasive pulmonary valve which is catheter based valve replacement. This is the only pulmonary valve in clinical trials now, which is delivered via a catheter for the patients with previous TOF procedures.
All three patients treated in Chile were discharged from the hospital within 1-5 days, respectively. All of them are doing well with normal daily activities now. One of the young patients mentioned that it was her first time since birth that she could hold her breath for longer than a few seconds.
With the first three successful Venus Pulmonary Valve replacements and immediate results, the Latin American doctors are very confident that many more patients can be treated with valves. The LATAM team is already planning to assist more patients in Chile, Argentina and Brazil.
Venus Medtech (Hangzhou) Inc. is located in Hangzhou National High-tech Industrial Development Zone (Binjiang), with its products positioned in the development and industrialization of international advanced interventional artificial cardiac valve system, in China. For more information visit en.venusmedtech.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-ever-venus-p-valve-implantations-in-latin-america-300247019.html
SOURCE Venus Medtech (Hangzhou) Inc.